Lupin and Hyderabad-based Natco Pharma have received USFDA approval for Eribulin Mesylate Injection, a generic version of Halaven used to treat metastatic breast cancer and advanced liposarcoma. The reference drug recorded annual US sales of approximately $43.7 million.
